GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hypha Labs Inc (OTCPK:DIGP) » Definitions » Shiller PE Ratio

Hypha Labs (Hypha Labs) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hypha Labs Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Hypha Labs Shiller PE Ratio Historical Data

The historical data trend for Hypha Labs's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hypha Labs Shiller PE Ratio Chart

Hypha Labs Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Hypha Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hypha Labs's Shiller PE Ratio

For the Diagnostics & Research subindustry, Hypha Labs's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hypha Labs's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Hypha Labs's Shiller PE Ratio falls into.



Hypha Labs Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Hypha Labs's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Hypha Labs's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.002/129.4194*129.4194
=0.002

Current CPI (Dec. 2023) = 129.4194.

Hypha Labs Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.500 99.695 -0.649
201406 -0.190 100.560 -0.245
201409 -0.320 100.428 -0.412
201412 -0.300 99.070 -0.392
201503 -0.100 99.621 -0.130
201506 -0.070 100.684 -0.090
201509 -0.020 100.392 -0.026
201512 -0.120 99.792 -0.156
201603 -0.030 100.470 -0.039
201606 -0.050 101.688 -0.064
201609 -0.010 101.861 -0.013
201612 -0.010 101.863 -0.013
201703 -0.010 102.862 -0.013
201706 -0.010 103.349 -0.013
201709 -0.010 104.136 -0.012
201712 -0.010 104.011 -0.012
201803 -0.020 105.290 -0.025
201806 -0.010 106.317 -0.012
201809 0.000 106.507 0.000
201812 -0.010 105.998 -0.012
201903 -0.010 107.251 -0.012
201906 -0.010 108.070 -0.012
201909 -0.010 108.329 -0.012
201912 -0.005 108.420 -0.006
202003 -0.010 108.902 -0.012
202006 -0.010 108.767 -0.012
202009 -0.010 109.815 -0.012
202012 -0.010 109.897 -0.012
202103 0.000 111.754 0.000
202106 -0.003 114.631 -0.003
202109 0.000 115.734 0.000
202112 -0.006 117.630 -0.007
202203 -0.005 121.301 -0.005
202206 -0.010 125.017 -0.010
202209 -0.010 125.227 -0.010
202212 -0.003 125.222 -0.003
202303 -0.001 127.348 -0.001
202306 0.003 128.729 0.003
202309 0.000 129.860 0.000
202312 0.002 129.419 0.002

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Hypha Labs  (OTCPK:DIGP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Hypha Labs Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Hypha Labs's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hypha Labs (Hypha Labs) Business Description

Traded in Other Exchanges
N/A
Address
6450 Cameron Street, Suite 113, Las Vegas, NV, USA, 89118
DigiPath Inc is engaged in providing pharmaceutical-grade analysis and testing cannabis education and training and brings unbiased cannabis news coverage to the cannabis industry. It screens medicinal cannabis for potentially harmful contaminants, including solvents, pesticides, mold and yeast, heavy metals such as mercury, arsenic, cadmium, and others. It also tests cannabis for its quality, potency, and cannabinoid and terpene profiles, which determine the suitability of specific cannabis strains for the treatment of specific ailments.
Executives
A Stone Douglass director 10200 WILLOW CREEK ROAD, SAN DIEGO CA 92131
Edmond Defrank director 19360 RINALDI STREET, #448, NORTHRIDGE CA 91326
Kyle Remenda officer: Chief Executive Officer 111-2532 SHORELINE DRIVE, LAKE COUNTRY A1 V4V2R6
Dennis Hartmann director 1600 CAMDEN AVENUE, NO. 103, LOS ANGELES CA 90025
Bruce I Raben director 430 VICTORIA TERRACE, RIDGEFIELD NJ 7657
Cindy Sue Orser director 4507 APPLE WAY, BOULDER CO 80301
Alfredo Axtmayer director 287 PAYNE DRIVE, CHESHIRE CT 06410
Joseph J Bianco director 611 BROADWAY,, SUITE 307, NEW YORK NY 10012
Todd A Peterson officer: Chief Financial Officer 3608 MALLARDWOOD DRIVE, LAS VEGAS NV 89129
Joe D Tanner director 28720 ROADSIDE DRIVE, SUITE 128, AGOURA HILLS CA 91301
Raw Alternative, Llc 10 percent owner 16030 VENTURA BLVD. SUITE 380, ENCINO CA 91436
Todd Denkin director, officer: President C/O PHOTOTRON, INC., 20259 VENTURA BLVD., WOODLAND HILLS CA 91364
Barbee Denny Barbee 10 percent owner 3105 EAST CENTRAL, #114, WICHITA KS 67214
Eric Stoppenhagen director, 10 percent owner, officer: CFO 8908 SPLITARROW DRIVE, AUSTIN TX 78717